Department of Nephrology, The First People's Hospital of Wenling &The Affiliated Wenling Hospital of Wenzhou Medical University. Wenling, 317500, Zhejiang, PR China.
Department of Nephrology, The First People's Hospital of Wenling &The Affiliated Wenling Hospital of Wenzhou Medical University. Wenling, 317500, Zhejiang, PR China.
Eur J Pharmacol. 2019 Oct 5;860:172536. doi: 10.1016/j.ejphar.2019.172536. Epub 2019 Jul 13.
Renal cell carcinoma (RCC) is one of the top ten deadly malignancies in the world. The long non-coding RNA taurine up-regulated gene 1 (TUG1) is a transcript that is up-regulated by taurine. There is ample evidence that TUG1 plays a crucial role in the progression of various cancers. This study aimed to investigate the role of TUG1 in RCC and its underlying molecular mechanisms. In the current study, knockdown of TUG1 by shRNA (sh-TUG1) significantly inhibited proliferation, invasion, migration and EMT processes of ACHN cells and OS-RC-2 cells, and induced apoptosis. Besides, bioinformatics analysis revealed that miR-299-3p is a target of TUG1. TUG1 overexpression (LV-TUG1) significantly inhibited the expression of miR-299-3p, whereas sh-TUG1 showed the opposite effect. Dual luciferase reporter assay further confirmed the targeting relationship between TUG1 and miR-299-3p. In addition, vascular endothelial growth factor (VEGFA) is a target of miR-299-3p. Knockdown of VEGFA (si-VEGFA) significantly inhibited the proliferation and motility of ACHN cells, and induced apoptosis. RT-qPCR results showed that sh-TUG1 similarly inhibited VEGFA expression. Further functional analysis indicated that sh-TUG1 inhibited tumorigenesis by down-regulating VEGFA levels. However, LV-TUG1 showed the opposite effects. Furthermore, animal experiments have shown that sh-TUG1 inhibited tumor growth and metastasis and induces apoptosis in vivo. These results indicate that sh-TUG1 inhibited renal cell carcinoma formation by miR-299-3p/VEGF axis in vitro and in vivo. Taken together, all of these results reveal a novel mechanism of TUG1 in RCC tumorigenesis, suggesting that targeted drugs for TUG1 provides a new direction for the treatment of RCC.
肾细胞癌(RCC)是世界十大致命恶性肿瘤之一。长链非编码 RNA 牛磺酸上调基因 1(TUG1)是一种由牛磺酸上调的转录物。有充分的证据表明,TUG1 在各种癌症的进展中起着关键作用。本研究旨在探讨 TUG1 在 RCC 中的作用及其潜在的分子机制。在本研究中,通过 shRNA(sh-TUG1)敲低 TUG1 显著抑制了 ACHN 细胞和 OS-RC-2 细胞的增殖、侵袭、迁移和 EMT 过程,并诱导细胞凋亡。此外,生物信息学分析显示 miR-299-3p 是 TUG1 的靶标。TUG1 过表达(LV-TUG1)显著抑制了 miR-299-3p 的表达,而 sh-TUG1 则表现出相反的效果。双荧光素酶报告基因实验进一步证实了 TUG1 与 miR-299-3p 之间的靶向关系。此外,血管内皮生长因子(VEGFA)是 miR-299-3p 的靶标。VEGFA 敲低(si-VEGFA)显著抑制了 ACHN 细胞的增殖和迁移,并诱导细胞凋亡。RT-qPCR 结果显示 sh-TUG1 同样抑制了 VEGFA 的表达。进一步的功能分析表明,sh-TUG1 通过下调 VEGFA 水平抑制肿瘤发生。然而,LV-TUG1 则表现出相反的效果。此外,动物实验表明,sh-TUG1 抑制了肿瘤的生长和转移,并在体内诱导了细胞凋亡。这些结果表明,sh-TUG1 通过 miR-299-3p/VEGF 轴在体内外抑制了肾癌细胞的形成。综上所述,这些结果揭示了 TUG1 在 RCC 肿瘤发生中的新机制,表明针对 TUG1 的靶向药物为 RCC 的治疗提供了新的方向。